Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2− Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series †

Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in combination with endocrine therapy (ET) show meaningful efficacy and tolerability in patients with metastatic breast cancer (MBC), but the optimal sequence of ET has not been established. It is not clear if patients with lobular breast carcinomas (...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:J Pers Med
المؤلفون الرئيسيون: Orlandi, Armando, Iattoni, Elena, Pizzuti, Laura, Fabbri, Agnese, Botticelli, Andrea, Di Dio, Carmela, Palazzo, Antonella, Garufi, Giovanna, Indellicati, Giulia, Alesini, Daniele, Carbognin, Luisa, Paris, Ida, Vaccaro, Angela, Moscetti, Luca, Fabi, Alessandra, Magri, Valentina, Naso, Giuseppe, Cassano, Alessandra, Vici, Patrizia, Giannarelli, Diana, Franceschini, Gianluca, Marchetti, Paolo, Bria, Emilio, Tortora, Giampaolo
التنسيق: Artigo
اللغة:Inglês
منشور في: MDPI 2020
الموضوعات:
Article
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC7766166/
https://ncbi.nlm.nih.gov/pubmed/33353132
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jpm10040291
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة